Skip to content
Menu

Inhibikase Therapeutics, Inc. IKT

Full chart Compare
Set alert

Price alert · IKT

All alert types
1.38 USD -0.07 (-4.83%)

Regular-session close

1.38 0.00 0.00%

After hours · Nov 17, 4:00 PM ET

1.37 Day range 1.49
1.37 52-week range 2.61
YTD
-32.68%
1 year
-9.21%
Market cap
193.57M
Revenue (ttm)
79.57K
EPS (ttm)
-0.38
Shares out
67.19M
Forward P/E
-11.84
YTD return
-32.68%
1-year return
-9.21%
50-day average
2.62
Volume
670.32K
Avg volume
570.83K
Open
1.45
Previous close
1.45
Day's range
1.37 – 1.49
52-week range
1.37 – 2.61
Beta
1.12
Price target
7.00 (+407.2%)

 

No chart data for this range yet.

Key statistics

200-day average
1.84
Enterprise value
10.03M
Price / sales
2499.56
Price / book
1.67
Free cash flow
-10.34M
Total cash
7.94M
Total debt
355.09K
Return on equity
-149.69%
Short % of float
0.29%

Fundamental scorecard

5 of 25 checks passed on IKT’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
IKT Revenue — quarterly 0
IKT Net income — quarterly -20.47M
IKT EPS — quarterly -0.10

Earnings

IKT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 2024-0.38-0.65-0.27-71.05%
Aug 14, 2024Jun 1, 2024-0.58-0.66-0.08-13.79%
Aug 14, 2024Jun 1, 2024-0.58———
May 15, 2024Mar 1, 2024-0.79-0.73+0.06+7.59%
May 15, 2024Mar 1, 2024-0.79———
Mar 27, 2024Dec 1, 2023-0.78-0.63+0.15+19.23%

Upgrades / downgrades

IKT analyst upgrades and downgrades
DateFirmActionFromTo
Nov 8, 2024Jefferiesinit—Buy
Oct 14, 2024HC Wainwright & Co.mainBuyBuy
Aug 16, 2024HC Wainwright & Co.mainBuyBuy
May 21, 2024HC Wainwright & Co.mainBuyBuy
Mar 7, 2024HC Wainwright & Co.reitBuyBuy
Mar 5, 2024HC Wainwright & Co.mainBuyBuy

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on IKT — it syncs with the Stock Master app.

Insider holders

IKT insider holders
InsiderRelationLatest transactionDateShares held
BELLINI ROBERTODirectorPurchaseOct 20, 20240
KUSH ARVINDDirectorPurchaseOct 20, 2024145,000
MUNSHI AMIT DDirectorPurchaseOct 20, 20240

Institution ownership

IKT institution ownership
Holder% heldSharesValueReported
Armistice Capital, LLC0.93%626,5001.85MSep 29, 2024
Blair (William) & Company, L.L.C.0.19%126,120373.31KSep 29, 2024
Geode Capital Management, LLC0.07%50,065148.19KSep 29, 2024
Renaissance Technologies, LLC0.03%19,92258.97KSep 29, 2024
Vanguard Group Inc0.02%16,72449.50KSep 29, 2024
State Street Corporation0.02%10,08429.85KSep 29, 2024

Fund ownership

IKT fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.05%36,382107.69KOct 30, 2024
360 Funds-Timber Point Global Tactical Allocation Fd0.02%11,00032.56KSep 29, 2024
Vanguard Extended Market Index Fund0.02%16,72449.50KSep 29, 2024
Fidelity Total Market Index Fund0.02%11,48433.99KOct 30, 2024
Fidelity Series Total Market Index Fund0.01%8,57725.39KOct 30, 2024
Fidelity NASDAQ Composite Index Fund0.00%3,2729.69KOct 30, 2024